Roche Palo Alto LLC

Novartis Ag

Ideaya Biosciences, Inc.

Genentech, Inc.

Syntex (u.s.a.) Inc.

Hoffmann-La Roche Inc.

Other

F. Hoffmann-La Roche Ag

Michael Patrick Dillon

Li Chen

Ronald Charles Hawley

Minmin Yang

Lichun Feng

Alam Jahangir

Clara Jeou Jen Lin

Savithri Ramurthy

Matthew T Burger

Sharadha Subramanian

Chris Allen Broka

David Scott Carter

Hilary Plake Beck

Daniel Warren Parish

Marcos Gonzalez-Lopez

James Clifford Sutton, Jr

Robert John Aversa

Yan Lou

Benjamin R Taft

Gisele A Nishiguchi

Lifeng Wan

Lina Quattrocchio Setti

Alice C Rico

Muzaffar Alam

Amy Geraldine Moore

Counde O'Yang

Aaron Matthew Smith

Paul Andrew Barsanti

Liladhar Murlidhar Waykole

Cheng Hu

Christoph Spiess

Nikolaus Johannes Stiefl

Lv Liao

Thomas Ullrich

Sven Weiler

Yue Pan

Naeem Yusuff

Luca Arista

Rene Lattmann

Vivek Rauniyar

Xiaoyang Wang

Rita Ramos

Dimitrios Lizos

Tingying Zhu

Huw Roland Tanner

Peggy Usselmann

Kai Cui

Valery Rostislavovich Polyakov

Yubo Zhang

Yizong Zhou

Sreehari Babu

Jianwei Bian

Jialiang Li

Xiaoming Zhang

Paul J Carter

Nancy Elisabeth Krauss

Yiyuan Yin

Jianhui Zhou

Yingjie Lai

Jacob Corn

Yansheng Zhai

Anthony P D W Ford

Matthias Heinrich Nettekoven

Hasane Ratni

Robin D Clark

Eric Brian Sjogren

Frederick Arthur Brookfield

Sabine Kolczewski

David Michael Goldstein

Guido Galley

Zhe Li

Daniel J Poon

Martin Sendzik

James Clifford Sutton

Bo Han

Cynthia Shafer

Ryan Craig Schoenfeld

Ralph New Harris, Iii

David Bruce Repke

Hans Maag

Annick Goergler

Leyi Gong

Christine E Brotherton-Pleiss

Mika Lindvall

Walter Vifian

Rajesh Karki

Robert Stephen Wilhelm

Joan Heather Hogg

Joan Marie Caroon

Xiaochun Han

Alfred Sui-Ting Lui

Xin Linghu

Karthik Veeravalli

Jaehyeon Park

Leah Cleary

David Llewellyn Coffen

Deborah Carol Reuter

Twyla Noelle Lombana

Patrick James Sarver

The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Aminopyridine derivatives and their use as selective ALK-2 inhibitors

Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. The provided compounds are useful Poly ADP-ribose glycohydrolase (PARG) inhibitors. Additional utilities and advantages are described herein.

Piperazine substituted indazole compounds as inhibitors of PARG

Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X, X, Z, R, R, R, R, R, R, Rand Rhave the meanings provided in the specification.

AhR modulators

Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.

Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.

Multispecific antigen-binding proteins

Compounds are provided having Formula (I): wherein R, R, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.

Dihydrothieno[3,2-b]pyridine compounds

Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R, Rand Rhave the meanings provided in the specification. 

Amido compounds as AhR modulators

The invention provides methods of identifying bacteria comprising binding polypeptides. The invention also provides methods of identifying bacteria with improved expression of binding polypeptides. The invention also provides methods of identifying binding polypeptides with improved expression. The invention also provides engineered bacteria suitable for use in the methods of the invention. The invention also provides compositions that can be obtained using the methods, for example, anti-interleukin-13 (IL-13) antibodies with improved expression and/or stability. The invention also provides libraries comprising binding polypeptide (e.g., antibody) variants.

Methods of identifying bacteria comprising binding polypeptides

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. 

The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Biaryl amide compounds as kinase inhibitors

The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers. 

Tricyclic compounds and compositions as kinase inhibitors

Growing community of inventors

San Carlos, CA, United States of America

Michael Patrick Dillon